Article activity feed

  1. SciScore for 10.1101/2021.11.28.468932: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    NIH rigor criteria are not applicable to paper type.

    Table 2: Resources

    Experimental Models: Organisms/Strains
    Bacterial transformations were performed on a chemically competent Escherichia coli BL21 Rosetta-2 strain for both constructs.
    suggested: None
    Software and Algorithms
    During the data collection the MESH injector system had no blockages.
    suggested: (MeSH, RRID:SCR_004750)
    We performed our initial rigid-body refinements through the PHENIX [40] software package.
    suggested: (Phenix, RRID:SCR_014224)
    The water molecules and strong difference density positions of the structures were checked using the COOT [41] software.
    suggested: (Coot, RRID:SCR_014222)
    Structural alignments and all figures were generated using the PyMOL [42] software.
    suggested: (PyMOL, RRID:SCR_000305)

    Results from OddPub: Thank you for sharing your data.

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    To overcome this limitation, we performed our soaking experiments with two different crystal forms to increase the likelihood of drug binding. Despite our attempts, we obtained structural results with only subtle differences in the active site during the HTS process. Co-crystallization, used as an alternative method, may provide more accurate structural data to demonstrate the interaction between Mpro and, not only montelukast and ebselen, but also the other drug candidates. In this study, 9 drug candidates were screened for binding in two different crystal forms. However, none of the samples displayed noticeable experimental electron densities, suggesting at 100 μg/ml concentration soaking experiments failed. Interestingly, a high amount of precipitation was observed in two drug-protein samples containing montelukast and ebselen. Montelukast is a selective leukotriene receptor antagonist and an FDA-approved drug used in the treatment of chronic and prophylactic asthma [17]. Previously, montelukast was observed to have immunomodulatory and antiviral activities against dengue and ZIKA viruses. Therefore, it was hypothesized that montelukast may also have antiviral activity against SARS-CoV-2 [27]. Studies related to SARS-CoV-2-montelukast interaction are mostly in silico- [44,45,46] and in vitro- [17,42] oriented. Accordingly, we suggest that although montelukast interacts with Mpro, it may interfere through an allosteric effect, disrupting its conformation and perturbing the ...

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • No funding statement was detected.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    Read the original source
    Was this evaluation helpful?